Related Experiment Video

Updated: May 10, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Safety of prophylactic anticoagulation at a pediatric hospital

Jonathan Stem1, Ashley Christensen, Daniela Davis

  • 1*Wake Forest Medical School, Winston-Salem, NC †University of Iowa Carver College of Medicine, Iowa City, Iowa ‡Division of Pediatric Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine §Department of Pediatrics, Division of Hematology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Journal of Pediatric Hematology/Oncology
|June 19, 2013
PubMed

Insights

This study evaluated anticoagulation safety in pediatric patients at high risk for venous thromboembolism (VTE). Major bleeding occurred in 4% of orthopedic surgery patients, with no VTE events observed.

Area of Science:

  • Pediatric Hematology
  • Hospital Medicine
  • Clinical Safety Research

Background:

  • Venous thromboembolism (VTE) prevention is crucial in hospitalized adults.
  • Institutional guidelines for VTE prevention in high-risk pediatric patients were recently established.
  • Evaluating the safety of anticoagulation post-guideline implementation is essential.

Purpose of the Study:

  • To assess the safety of anticoagulation therapy in hospitalized pediatric patients following new VTE prevention guidelines.
  • To determine the incidence of major and minor bleeding events.
  • To evaluate the occurrence of VTE in this patient cohort.

Main Methods:

  • Prospective observational study design.
  • Enrollment of 89 high-risk pediatric patients (mean age 16.6 years).
  • Monitoring for major bleeding, minor bleeding, and VTE events.

Main Results:

  • Two major bleeding events occurred (4% incidence), exclusively in patients undergoing major orthopedic surgery.
  • Minor bleeding occurred in 5 patients (all post-orthopedic surgery).
  • No non-catheter-related VTE events were recorded.

Conclusions:

  • Anticoagulation for VTE prophylaxis in high-risk pediatric patients appears relatively safe, particularly with careful consideration in orthopedic surgery cases.
  • The implemented guidelines successfully prevented VTE events.
  • Further research is needed to refine VTE prophylaxis strategies and risk-benefit profiles in pediatric populations.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...